Insider · CIK 0001944884
Sandra Beaver
Files at TNDM (TANDEM DIABETES CARE INC), EOLS (Evolus, Inc.). First filing Dec 26, 2024, latest May 14, 2025.
Sandra Beaver files SEC Form 4 as CFO and director at EOLS (Evolus, Inc.), and also at TNDM (TANDEM DIABETES CARE INC). Since Dec 26, 2024, Sandra Beaver has reported 0 open-market buys worth $0 and 3 open-market sells worth $202k, the latest filed on May 14, 2025.
A track record needs three past buys with six months of prices behind them; Sandra Beaver has 0, so none is measured yet.
The newest scored trade: sold $65k of EOLS on May 13, 2025, filed May 14, 2025, scored 25 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EOLS: Evolus, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Evolus, Inc. | $65k 6,494 shares | -4% | +8% from low-42% from high | |
| 27Weak | Evolus, Inc. | $119k 8,996 shares | -5% | - | |
| 17Weak | Evolus, Inc. | $17k 1,586 shares | -1% | - |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | TNDM TANDEM DIABETES CARE INC | AGrant or award Restricted Stock Unitderivative | +5,110 | $0.00 | $0 | 5,110 | May 22, 2026 |
| Nov 7, 2025 | TNDM TANDEM DIABETES CARE INC | AGrant or award Restricted Stock Unitderivative | +20,242 | $0.00 | $0 | 20,242 | Nov 25, 2025 |
| May 13, 2025 | EOLS Evolus, Inc. | SOpen-market sale Common Stock10b5-1 | -6,494 | $10.02 | $65k | 167,089 | May 14, 2025 |
| Mar 18, 2025 | EOLS Evolus, Inc. | SOpen-market sale Common Stock10b5-1 | -8,996 | $13.26 | $119k | 173,583 | Mar 20, 2025 |
| Mar 7, 2025 | EOLS Evolus, Inc. | AGrant or award Common Stock | +35,663 | $0.00 | $0 | 182,579 | Mar 11, 2025 |
| Mar 7, 2025 | EOLS Evolus, Inc. | AGrant or award Performance Restricted Stock Unitsderivative | +35,663 | $0.00 | $0 | 35,663 | Mar 11, 2025 |
| Mar 7, 2025 | EOLS Evolus, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +50,813 | $0.00 | $0 | 50,813 | Mar 11, 2025 |
| Dec 23, 2024 | EOLS Evolus, Inc. | SOpen-market sale Common Stock10b5-1 | -1,586 | $10.85 | $17k | 146,916 | Dec 26, 2024 |
Questions about Sandra Beaver
Answered from the filings on this page, as of the latest one.
Is Sandra Beaver buying or selling?
Not in the last 12 months. Sandra Beaver's latest open-market trade on SEC Form 4 was sold $65k of EOLS on May 13, 2025.
How did Sandra Beaver's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sandra Beaver has 0.
Where does Sandra Beaver file Form 4?
Sandra Beaver has filed Form 4 at EOLS (Evolus, Inc.) as Chief Financial Officer; TNDM (TANDEM DIABETES CARE INC). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.